Prompted by these promising results obtained in preclinical models, phase I and II clinical trials are evaluating the targeting of CXCR1 and CXCR2 in combination with anti-PD-1 in patients with metastatic melanoma, pancreatic ductal carcinoma, and Ras-mutated MSS metastatic colon carcinoma [157]. This evidence concerns the gene CXCR1 and pancreatic ductal adenocarcinoma.